CTLA4 and neoplasm: The immune checkpoint pathways PD-1 and cytotoxic T-lymphocyte associated antigen 4 (CTLA-4, also known as CD152) decrease T-lymphocyte activation, inducing an immunosuppressive state to maintain peripheral tolerance, but this can be taken advantage of by tumor cells that multiply, grow, and develop rapidly instead of being eliminated by the immune system.